EA202190544A1 - Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний - Google Patents

Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний

Info

Publication number
EA202190544A1
EA202190544A1 EA202190544A EA202190544A EA202190544A1 EA 202190544 A1 EA202190544 A1 EA 202190544A1 EA 202190544 A EA202190544 A EA 202190544A EA 202190544 A EA202190544 A EA 202190544A EA 202190544 A1 EA202190544 A1 EA 202190544A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oral cavity
riluzol
disposing
tablets
diseases
Prior art date
Application number
EA202190544A
Other languages
English (en)
Inventor
Владимир Корик
Original Assignee
Биохэйвен Терапьютикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биохэйвен Терапьютикс Лтд. filed Critical Биохэйвен Терапьютикс Лтд.
Publication of EA202190544A1 publication Critical patent/EA202190544A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Раскрыты способы лечения заболевания у пациента, нуждающегося в этом, включающие введение пациенту фармацевтической композиции, содержащей терапевтически эффективное количество рилузола или его фармацевтически приемлемой соли или пролекарства, в виде твердой формованной лекарственной формы, быстро диспергируемой в полости рта. Также раскрыты фармацевтические композиции и наборы.
EA202190544A 2018-08-16 2019-08-15 Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний EA202190544A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862764864P 2018-08-16 2018-08-16
PCT/US2019/046709 WO2020037152A1 (en) 2018-08-16 2019-08-15 Use of riluzole oral disintigrating tablets for treating diseases

Publications (1)

Publication Number Publication Date
EA202190544A1 true EA202190544A1 (ru) 2021-06-18

Family

ID=69525906

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190544A EA202190544A1 (ru) 2018-08-16 2019-08-15 Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний

Country Status (14)

Country Link
US (1) US20210315865A1 (ru)
EP (1) EP3836922B1 (ru)
JP (2) JP2021534160A (ru)
KR (1) KR20210045423A (ru)
CN (1) CN112584831A (ru)
AU (1) AU2019322889A1 (ru)
BR (1) BR112021002692A2 (ru)
CA (1) CA3109769A1 (ru)
EA (1) EA202190544A1 (ru)
IL (1) IL280657A (ru)
MX (2) MX2021001563A (ru)
PH (1) PH12021550218A1 (ru)
SG (1) SG11202100880VA (ru)
WO (1) WO2020037152A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021262914A1 (en) * 2020-06-24 2021-12-30 Biohaven Therapeutics Ltd. Compositions and methods for treating obsessive-compulsive disorder
WO2022076321A1 (en) * 2020-10-05 2022-04-14 Icahn School Of Medicine At Mount Sinai Riluzole for the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114177153B (zh) * 2021-12-20 2023-04-07 平顶山市第二人民医院 一种利鲁唑口崩片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
MXPA05005528A (es) * 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
US9241902B2 (en) * 2003-12-17 2016-01-26 R.P. Scherer Technologies, Llc Chewable soft capsules containing ungelatinized starch
EP1874353A1 (en) * 2005-04-05 2008-01-09 Yale University Glutamate modulating agents in the treatment of mental disorders
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP5859438B2 (ja) * 2009-08-10 2016-02-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いたｂｄｎｆ関連疾患の治療
US9041556B2 (en) 2011-10-20 2015-05-26 Apple Inc. Method for locating a vehicle
US9434704B2 (en) * 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
SI3220891T1 (sl) * 2014-11-21 2020-02-28 Biohaven Therapeutics Ltd. Podjezična formulacija riluzola
CA2967659A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
JP6827924B2 (ja) * 2014-11-26 2021-02-10 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラスト及びリルゾールの組み合わせを含む医薬および組成物
CN107567438B (zh) * 2015-03-03 2021-06-29 拜尔哈文制药股份有限公司 利鲁唑前药及其用途
US20180214395A1 (en) * 2017-01-31 2018-08-02 Paolo L. Manfredi Compounds for Treatment or Prevention of Disorders of the Nervous System and Symptoms and Manifestations Thereof, and for Cyto-Protection Against Diseases and Aging of Cells, and Symptoms and Manifestations Thereof

Also Published As

Publication number Publication date
WO2020037152A1 (en) 2020-02-20
EP3836922C0 (en) 2024-08-07
AU2019322889A1 (en) 2021-03-04
IL280657A (en) 2021-03-25
EP3836922A1 (en) 2021-06-23
PH12021550218A1 (en) 2021-12-06
MX2021001563A (es) 2021-06-15
US20210315865A1 (en) 2021-10-14
EP3836922B1 (en) 2024-08-07
EP3836922A4 (en) 2022-05-04
SG11202100880VA (en) 2021-02-25
JP2024010017A (ja) 2024-01-23
BR112021002692A2 (pt) 2021-05-11
CA3109769A1 (en) 2020-02-20
KR20210045423A (ko) 2021-04-26
CN112584831A (zh) 2021-03-30
MX2024007642A (es) 2024-07-04
JP2021534160A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PH12019500025A1 (en) Cancer treatment combinations
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2024006271A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2023005462A (es) Compuestos macrociclicos y metodos para usarlos.
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
RU2013105513A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
EA202092944A1 (ru) Применение пероральных распадающихся таблеток рилузола для лечения заболеваний
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MX2021015796A (es) Composiciones y metodos para tratar enfermedades oculares.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
MX2021008658A (es) Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk).
RU2018119120A (ru) D-пролиновые производные в качестве агента, уменьшающего количество sap
JP2017509683A5 (ru)
RU2014125701A (ru) Фармацевтическая композиция для профилактики или лечения гипертриглицеридемии или вызванных гипертриглицеридемией заболеваний
EA202091162A1 (ru) Применение пролекарств рилузола для лечения атаксии